203 related articles for article (PubMed ID: 28154202)
1. Aspirin-Induced Chemoprevention and Response Kinetics Are Enhanced by PIK3CA Mutations in Colorectal Cancer Cells.
Zumwalt TJ; Wodarz D; Komarova NL; Toden S; Turner J; Cardenas J; Burn J; Chan AT; Boland CR; Goel A
Cancer Prev Res (Phila); 2017 Mar; 10(3):208-218. PubMed ID: 28154202
[TBL] [Abstract][Full Text] [Related]
2. Aspirin has a better effect on PIK3CA mutant colorectal cancer cells by PI3K/Akt/Raptor pathway.
Chen Z; Wang C; Dong H; Wang X; Gao F; Zhang S; Zhang X
Mol Med; 2020 Jan; 26(1):14. PubMed ID: 32000660
[TBL] [Abstract][Full Text] [Related]
3. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival.
Liao X; Lochhead P; Nishihara R; Morikawa T; Kuchiba A; Yamauchi M; Imamura Y; Qian ZR; Baba Y; Shima K; Sun R; Nosho K; Meyerhardt JA; Giovannucci E; Fuchs CS; Chan AT; Ogino S
N Engl J Med; 2012 Oct; 367(17):1596-606. PubMed ID: 23094721
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive in vivo and mathematic modeling-based kinetic characterization for aspirin-induced chemoprevention in colorectal cancer.
Shimura T; Toden S; Komarova NL; Boland C; Wodarz D; Goel A
Carcinogenesis; 2020 Jul; 41(6):751-760. PubMed ID: 31904094
[TBL] [Abstract][Full Text] [Related]
5. Aspirin Suppresses Growth in PI3K-Mutant Breast Cancer by Activating AMPK and Inhibiting mTORC1 Signaling.
Henry WS; Laszewski T; Tsang T; Beca F; Beck AH; McAllister SS; Toker A
Cancer Res; 2017 Feb; 77(3):790-801. PubMed ID: 27940576
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer.
Hao Y; Samuels Y; Li Q; Krokowski D; Guan BJ; Wang C; Jin Z; Dong B; Cao B; Feng X; Xiang M; Xu C; Fink S; Meropol NJ; Xu Y; Conlon RA; Markowitz S; Kinzler KW; Velculescu VE; Brunengraber H; Willis JE; LaFramboise T; Hatzoglou M; Zhang GF; Vogelstein B; Wang Z
Nat Commun; 2016 Jun; 7():11971. PubMed ID: 27321283
[TBL] [Abstract][Full Text] [Related]
7. Fisetin and 5-fluorouracil: Effective combination for PIK3CA-mutant colorectal cancer.
Khan N; Jajeh F; Eberhardt EL; Miller DD; Albrecht DM; Van Doorn R; Hruby MD; Maresh ME; Clipson L; Mukhtar H; Halberg RB
Int J Cancer; 2019 Dec; 145(11):3022-3032. PubMed ID: 31018249
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-375 inhibits colorectal cancer growth by targeting PIK3CA.
Wang Y; Tang Q; Li M; Jiang S; Wang X
Biochem Biophys Res Commun; 2014 Feb; 444(2):199-204. PubMed ID: 24440701
[TBL] [Abstract][Full Text] [Related]
9. Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer.
Kim A; Lee JE; Lee SS; Kim C; Lee SJ; Jang WS; Park S
Int J Cancer; 2013 Aug; 133(4):984-96. PubMed ID: 23475782
[TBL] [Abstract][Full Text] [Related]
10. Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.
Nakayama I; Shinozaki E; Matsushima T; Wakatsuki T; Ogura M; Ichimura T; Ozaka M; Takahari D; Suenaga M; Chin K; Mizunuma N; Yamaguchi K
BMC Cancer; 2017 Jan; 17(1):38. PubMed ID: 28068936
[TBL] [Abstract][Full Text] [Related]
11. Lysine-Specific Demethylase 1 Mediates AKT Activity and Promotes Epithelial-to-Mesenchymal Transition in
Miller SA; Policastro RA; Savant SS; Sriramkumar S; Ding N; Lu X; Mohammad HP; Cao S; Kalin JH; Cole PA; Zentner GE; O'Hagan HM
Mol Cancer Res; 2020 Feb; 18(2):264-277. PubMed ID: 31704733
[TBL] [Abstract][Full Text] [Related]
12. Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology.
Ogino S; Lochhead P; Giovannucci E; Meyerhardt JA; Fuchs CS; Chan AT
Oncogene; 2014 Jun; 33(23):2949-55. PubMed ID: 23792451
[TBL] [Abstract][Full Text] [Related]
13. MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.
García-García C; Rivas MA; Ibrahim YH; Calvo MT; Gris-Oliver A; Rodríguez O; Grueso J; Antón P; Guzmán M; Aura C; Nuciforo P; Jessen K; Argilés G; Dienstmann R; Bertotti A; Trusolino L; Matito J; Vivancos A; Chicote I; Palmer HG; Tabernero J; Scaltriti M; Baselga J; Serra V
Clin Cancer Res; 2015 Dec; 21(24):5499-5510. PubMed ID: 26272063
[TBL] [Abstract][Full Text] [Related]
14. Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.
Napolitano S; Martini G; Rinaldi B; Martinelli E; Donniacuo M; Berrino L; Vitagliano D; Morgillo F; Barra G; De Palma R; Merolla F; Ciardiello F; Troiani T
Clin Cancer Res; 2015 Jul; 21(13):2975-83. PubMed ID: 25838391
[TBL] [Abstract][Full Text] [Related]
15. Combination of COX-2 expression and PIK3CA mutation as prognostic and predictive markers for celecoxib treatment in breast cancer.
Tury S; Becette V; Assayag F; Vacher S; Benoist C; Kamal M; Marangoni E; Bièche I; Lerebours F; Callens C
Oncotarget; 2016 Dec; 7(51):85124-85141. PubMed ID: 27835884
[TBL] [Abstract][Full Text] [Related]
16. Aspirin exerts high anti-cancer activity in
Gu M; Nishihara R; Chen Y; Li W; Shi Y; Masugi Y; Hamada T; Kosumi K; Liu L; da Silva A; Nowak JA; Twombly T; Du C; Koh H; Li W; Meyerhardt JA; Wolpin BM; Giannakis M; Aguirre AJ; Bass AJ; Drew DA; Chan AT; Fuchs CS; Qian ZR; Ogino S
Oncotarget; 2017 Oct; 8(50):87379-87389. PubMed ID: 29152088
[TBL] [Abstract][Full Text] [Related]
17. Aspirin sensitivity of PIK3CA-mutated Colorectal Cancer: potential mechanisms revisited.
Hall DCN; Benndorf RA
Cell Mol Life Sci; 2022 Jul; 79(7):393. PubMed ID: 35780223
[TBL] [Abstract][Full Text] [Related]
18. Mutations in PIK3CA sensitize breast cancer cells to physiologic levels of aspirin.
Turturro SB; Najor MS; Ruby CE; Cobleigh MA; Abukhdeir AM
Breast Cancer Res Treat; 2016 Feb; 156(1):33-43. PubMed ID: 26915040
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of PIK3CA via antibody-esiRNA-complexes suppresses human xenograft tumor growth.
Bäumer N; Rehkämper J; Appel N; Terheyden L; Hartmann W; Wardelmann E; Buchholz F; Müller-Tidow C; Berdel WE; Bäumer S
PLoS One; 2018; 13(7):e0200163. PubMed ID: 30001368
[TBL] [Abstract][Full Text] [Related]
20. 5-Fluorouracil Enhances the Antitumor Activity of the Glutaminase Inhibitor CB-839 against
Zhao Y; Feng X; Chen Y; Selfridge JE; Gorityala S; Du Z; Wang JM; Hao Y; Cioffi G; Conlon RA; Barnholtz-Sloan JS; Saltzman J; Krishnamurthi SS; Vinayak S; Veigl M; Xu Y; Bajor DL; Markowitz SD; Meropol NJ; Eads JR; Wang Z
Cancer Res; 2020 Nov; 80(21):4815-4827. PubMed ID: 32907836
[No Abstract] [Full Text] [Related]
[Next] [New Search]
